Market closedNon-fractional
CG Oncology/CGON
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About CG Oncology
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Ticker
CGON
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Irvine, United States
Employees
61
Website
cgoncology.com
CG Oncology Metrics
BasicAdvanced
$2.2B
Market cap
-
P/E ratio
-$4.78
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$2.2B
Financial strength
Current ratio
57.954
Quick ratio
56.757
Long term debt to equity
0.032
Total debt to equity
0.071
Management effectiveness
Valuation
Price to revenue (TTM)
932.165
Price to book
3.87
Price to tangible book (TTM)
3.87
Price to free cash flow (TTM)
-7.885
Growth
What the Analysts think about CG Oncology
Analyst Ratings
Majority rating from 5 analysts.
CG Oncology Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$500K
∞%
Net income
-$17M
4.97%
Profit margin
-3,380.00%
-∞%
CG Oncology Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Actual
-$4.37
-$0.36
-
Expected
$0.00
-$0.29
-$0.37
Surprise
-∞%
24.14%
-
CG Oncology News
AllArticlesVideos
CG Oncology Bringing Undervalued Innovation To Bladder Cancer
Seeking Alpha·2 weeks ago
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
GlobeNewsWire·2 months ago
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for CG Oncology stock?
CG Oncology (CGON) has a market cap of $2.2B as of July 25, 2024.
What is the P/E ratio for CG Oncology stock?
The price to earnings (P/E) ratio for CG Oncology (CGON) stock is 0 as of July 25, 2024.
Does CG Oncology stock pay dividends?
No, CG Oncology (CGON) stock does not pay dividends to its shareholders as of July 25, 2024.
When is the next CG Oncology dividend payment date?
CG Oncology (CGON) stock does not pay dividends to its shareholders.
What is the beta indicator for CG Oncology?
CG Oncology (CGON) does not currently have a Beta indicator.
Buy or sell CG Oncology stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.